Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: "Folate overrescue" concept revisited

Clinical Chemistry

Volumn 52, Issue 4, 2006, Pages 692-700

  Sterba, Jaroslav ^a   Dusek, Ladislav ^b   Demlova, Regina ^c   Valik, Dalibor ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; FOLINIC ACID; HEMOGLOBIN; HOMOCYSTEINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; MALE; NONHODGKIN LYMPHOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INFANT; LEUCOVORIN; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 33645454373     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.061150     Document Type: Article

References (40)

1. Hill FG, Richards S, Gibson B, Hann I, Lilleyman J, Kinsey S, et al. The UK Medical Research Council Working Party on Childhood Leukemia. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004:124:33-46.
2. Cohen IJ. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 2004;26:156-63.
3. Sterba J, Valik D, Bajciova V, Kadlecova V, Gregorova V, Mendelova D. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when, and how? Neoplasma 2005;6:456-63.
4. Balis MF, Holcenberk JC, Blaney SM, General principles of chemotherapy. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia: Lippincott, 2002:237-308.
5. Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol 1998;16:920-30.
6. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia: Lippincott, 2002:516.
7. Borsi JD, Moe PJ. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 1987;60:3020-4.
8. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 2003;21:1798-809.
9. Mantadakis E, Cole PD, Kamen BA. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy 2005;25:748-55.
10. Borsi JD, Sagen E, Romslo I, Moe PJ. Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. Pediatr Hematol Oncol 1990;7:347-63.
11. Kamen BA. High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how? J Pediatr Hematol Oncol 2004;26:333-5.
12. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003;22:7431-57.
13. Djerassi I. Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report. Cancer Res 1967;27:2561-4.
14. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005;105:948-58.
15. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995, Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-22.
16. Capizzi RL. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 1981;65(Suppl 4):115-21.
17. Lobel JS, O'Brien RT, McIntosh S, Aspnes GT, Capizzi RL. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood. Cancer 1979;43:1089-94.
18. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-1671.
19. National Cancer Institute, U.S. National Institutes of Health. Phase III randomized study of dexamethasone versus prednisone during induction and high-dose methotrexate with leucovorin rescue versus escalating-dose methotrexate without leucovorin rescue during interim maintenance I in patients with newly diagnosed high-risk acute lymphoblastic leukemia http://www.cancer. gov/crinicaltrials/COG-AALL0232 (accessed September 2005).
20. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003;21:3084-91.
21. Refsum H, Ueland PM, Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986;46:5385-91.
22. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
23. Broxson EH Jr, Stork LC, Allen RH, Stabler SP, Kolhouse JF. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989;49:5879-83.
24. Ueland PM, Refsum H, Male R, Lillehaug JR. Disposition of endogenous homocysteine by mouse fibroblast C3H/10T1/2 CI 8 and the chemically transformed C3H/10T1/2 MCA CI 16 cells following methotrexate exposure. J Natl Cancer Inst 1986;77:283-9.
25. Valik D, Radina M, Sterba J, Vojtesek B. Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy. Pharmacogenomics 2004;5:1151-62.
26. Valik D, Sterba J, Bajciova V, Demlova R. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology 2005;69:269-72.
27. Snedecor GW, Cochran WG. Statistical methods, 7th ed. Ames, IA: Iowa State University Press, 1980.
28. Parkin TB, Robinson JA. Analysis of lognormal data. Adv Soil Sci 1992;20:193-235.
29. Kleijnen JPC. Statistical tools for simulation practitioners. New York: Marcel Dekker, 1987:429pp.
30. Parkin TB, Chester ST, Robinson JA. Evaluation of methods for calculating confidence intervals about the mean of a lognormally distributed variable. Soil Sci Soc Am J 1990;54:321-6.
31. Zar JH. Biostatistical analysis, 2nd ed. London: Prentice Hall, 1984:718pp.
32. US Food and Drug Administration, Center for Drug Evaluation and Research. Toxicity criteria, http://www.fda.gov/cder/cancer/toxicityframe.htm (accessed September 2005).
33. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.
34. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005;115:110-7.
35. Miklos GL, Maleszka R. Microarray reality checks in the context of a complex disease. Nat Biotechnol 2004;22:615-21.
36. Borsi JD, Wesenberg F, Stokland T, Moe PJ. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukemia. Eur J Cancer 1991;27:1006-9.
37. Hills RJ, Ive FA. Folinic acid rescue used routinely in psoriatic patients with known methotrexate "sensitivity". Acta Derm Venereol 1992;72:438-40.
38. Takacs P, Rodriguez L. High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy. Int J Gynaecol Obstet 2005;89:301-2.
39. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, et al. H. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM group. Blood 1991;78:1166-72.
40. Herold R, von Stackelberg A, Hartmann R, Eisenreich B, Henze G. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference. J Clin Oncol 2004;22:569-70.